Audit: QRS - Ginger for Health & Longevity

Audit conducted on 03/09/2026 05:32 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to the ER: at_a_glance to Conclusion (ER 540, 544); protocol cells to Therapeutic Protocol (ER 403, 411, 415); time cells to Practical Considerations (ER 460) and ER 405; benefit/risk tiers to the Expected Benefits and Potential Risks & Side Effects headings; gates to Key Interactions & Contraindications (ER 343–379); monitoring table and cadence to ER 490–502; qualitative items to ER 506–516.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The QRS carries the ER’s hedging where it is used, e.g. “Effects on blood fats, body weight and headache are inconsistent” mirrors ER 540 “inconsistent between analyses”. No hedge is dropped.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications keep avoidance framing (ER 369–379) and interactions keep interaction framing (ER 343–363); no gate is moved between the stop and caution lists.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Nothing from Benefit-Modifying Factors (ER 260–268) or Risk-Modifying Factors (ER 330–338) appears in the gates or the Risk card; each QRS section draws only from its mandated ER section.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS contains no PMIDs, citations, expert names, NCT identifiers, or brand names.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Flat, declarative, evidence-first register throughout, matching the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Doses, thresholds and biomarker ranges are given plainly, with tolerability framed as an actionable ceiling rather than a warning.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements describe what trials did (“Divided doses of 500 mg produced the cleanest nausea results”) rather than instructing the reader.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative or prescriptive constructions; the only advisory text is the fixed template disclaimer in the footer.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instance of “recommend”, “advise”, “should”, or “guidance” in the document body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained are load-bearing decision-gate content (e.g., “Los Angeles grade C or D”, “narrow-therapeutic-index CYP3A4 substrates”); the At-A-Glance and Qualitative Assessment cards are plain.
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are single clauses; monitoring rows are three short cells.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for “you”/”your”; no matches.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal functional biomarker ranges, split dosing and a monitoring cadence assume a proactive self-optimising reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Twice-weekly fasting glucose, weekly home blood pressure and nine-biomarker panels are presented without softening for convenience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Functional targets sit well below conventional cut-offs (e.g., hs-CRP below 0.8 mg/L), which is a longevity-audience framing, not a general-population one.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance states the benefit is conditional on raised starting values, which is the key distinction for an already-optimised reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears in the title and header; “anti-aging” appears nowhere.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Body cards use formal terms (“gastrointestinal irritation”, “glycated haemoglobin”, “erosive oesophagitis”); the plain-language wording is confined to At-A-Glance, where item 7.4 requires it.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings match the template byte-for-byte (QRS lines 446, 492, 541, 575, 594, 624, 653, 657–659, 804 and the four tier labels in both tier cards).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Diff of the extracted data-qrs-var name sets shows full coverage: all 36 fixed template names present, with marker_#_* expanded to marker_1–marker_9 and qualitative_item_# to items 1–6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three non-variable spans website="evidence_review", website="audit" and website="full_review" are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section feeding the QRS is empty; every benefit tier, risk tier, gate list, monitoring row and qualitative marker has ER content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1_label “Standard dose range”, action_2_label “Single versus split dosing” and action_3_label “Best time of day” reproduce the ER bold labels at ER 403, 415 and 411; monitoring row labels reproduce the ER biomarker column verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No ER-derived bold label is altered. The Time-to-Effect cell labels have no ER bold-label counterpart (the ER carries a single “Time to effect:” bullet) and are drawn directly from that bullet’s own subjects.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Full-text scan returns zero occurrences of 🟩/🟥/🟨 or the ER’s ⚠️ “Conflicted” markers; tiers are conveyed by CSS palettes and bold labels.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to its minimum mandated form — gate and tier items are single clauses with no rationale, monitoring “Why” cells are one line each, and the ER’s per-item context notes are dropped. The A4 print block and the 780px fallback are intact.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14 hold the sole metadata comment, immediately after <!doctype html> on line 1 and before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the “QRS — Metadata (invisible, parsed by audit tooling)” text precedes the opener.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values are repeated in the header, footer or any card.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values unquoted and trimmed except duration: "00:03", which contains a colon and therefore requires quoting.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: ginger_2026-0903-0140_Opus_ER.md, matching the ER’s own filename field (ER 17).
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the head of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0903-0529, correct YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word carrying no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number only.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: ginger_2026-0903-0140_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including git_user: evipedia-6 and git_issue: 5741; only the colon-bearing duration is quoted.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Ginger for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic (ER 8) with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Ginger for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/03/2026”, the correct MM/DD/YYYY rendering of qrs_creation_date: 2026-0903-0529.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter qrs_creator_ai_fullname.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header holds only the title and the template subline; the ER’s “Also known as” line (ER 30) is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses the four load-bearing findings of ER 540 and 544 — where nausea relief holds, the pain gradient, the baseline-dependent metabolic effect, and the tolerability ceiling.
7.2	[at_a_glance] is no longer than 60 words	🟢	Programmatic word count of the extracted span text: exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Nausea gradient and pain/metabolic claims from ER 540; the inconsistency of lipids, weight and headache from ER 540; the stomach-irritation ceiling from ER 544.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “blood sugar”, “blood fats”, “stomach irritation” and “heartburn” in place of glucose, lipids and gastro-oesophageal reflux; no acronyms present.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No author names, years, participant counts or p-values appear.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric result of any kind; effects are described qualitatively (“modestly”, “more strongly”).

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items map to the “Populations who should avoid Ginger” list at ER 369–379.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete one-to-one coverage of the six ER avoid-population bullets; none added, none omitted.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six discrete <li> elements at QRS lines 578–589, all inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No dashes and no trailing clauses; the ER’s plain-language glosses (“a blocked bile duct”, “acid damage to the food pipe lining”) are stripped, leaving only the gate fact.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All decision-relevant qualifiers survive: “below 50,000/µL”, “Within 7 days”, “Los Angeles grade C or D”, “above 1 g/day”, “first trimester”, and the Zingiberaceae example list.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication bullets use no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six avoid-populations, and the section is correspondingly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty, so no empty-state comment is required.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eleven items map to the bulleted interaction list at ER 343–363.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Eleven of the ER’s twelve interaction bullets are carried; the twelfth (“Elective surgery and endoscopic procedures”, ER 365) is correctly excluded because it is already the contraindication “Within 7 days of scheduled surgery or an invasive procedure”.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eleven discrete <li> elements at QRS lines 597–614, all inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is a drug class plus its example list; the ER’s severity words, mechanisms and mitigation sentences are all stripped, and no dashes appear.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER parenthetical is retained; three are trimmed for budget rather than dropped (“calcium carbonate antacids” → “antacids”, “beetroot or dietary nitrate” → “dietary nitrate”, removal of “high-dose vitamin E” from the bleeding-risk list).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction parentheticals are plain comma-separated drug lists with no ranking notation.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names twelve interactions, and the section is correspondingly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty, so no empty-state comment is required.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells draw from Therapeutic Protocol (ER 401–427).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose amount (ER 403), dose frequency (ER 415) and dose timing (ER 411) — the three decisions required to act, with the remaining ER bullets being refinements of these.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section carries thirteen actionable bullets, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated: “0.5–3 g/day” with the tolerability ceiling (ER 403), “Split” with the 500 mg divided-dose rationale (ER 415), and “With meals” with the pre-trigger window and half-life note (ER 411).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER’s “Time to effect” bullet (ER 460) names exactly three horizons — nausea, menstrual pain, and the joint/soreness/metabolic cluster — and all three are carried.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Menstrual pain first (largest quantified effect, SMD −1.13 at ER 171), nausea second (ER 159; graded the strongest indication by the umbrella review at ER 157), the osteoarthritis cluster last (SMD −0.30 at ER 165).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated with ER-derived values: “First cycle”, “30–60 minutes” and “3–12 weeks”, each with a sub drawn from ER 460 (and ER 405 for the menstrual start timing).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information at ER 460, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All seventeen listed benefits correspond to the ER’s Expected Benefits headings (ER 153–255), tier for tier.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at QRS lines 543, 550, 557 and 563.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the ER benefit heading alone; every “Magnitude” figure, mechanism sentence and evidence description from the ER is stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER benefit headings carry no parentheses, and the ER’s “⚠️ Conflicted” markers are correctly dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	The ER populates all four benefit tiers, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight listed risks correspond to the ER’s Potential Risks & Side Effects headings (ER 275–325), tier for tier.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at QRS lines 626, 629, 635 and 642.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the ER risk heading alone; the dose thresholds, mechanisms and magnitude figures from ER 279–325 are all stripped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER risk headings carry no parentheses, and the ER’s “⚠️ Conflicted” markers are correctly dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	The ER populates all four risk tiers, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table and cadence are taken from Monitoring Protocol & Defining Success (ER 486–502).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER table rows are present in order — fasting glucose, glycated haemoglobin, hs-CRP, home blood pressure, fasting triglycerides, LDL cholesterol, alanine aminotransferase, INR and blood lead — with targets reproduced verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS lines 793–798 carry the full ER cadence from ER 490: baseline, 8-week and 6-month rechecks, then annually, with weekly symptom/blood-pressure tracking and twice-weekly fasting glucose on insulin or a secretagogue.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items come from the “Qualitative markers worth tracking” list at ER 504–516.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Complete one-to-one coverage of the six ER qualitative markers, reproduced verbatim and in ER order.

Issues 03/09/2026 05:32

Pass rate 100.00%. No issues found.